Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Advaxis, Inc. - Common Stock (OP:ADXS)

0.0510 -0.0381 (-42.76%)
Streaming Delayed Price Updated: 2:53 PM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Advaxis, Inc. - Common Stock

News headline image
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
From Immunome, Inc.
Via Business Wire
News headline image
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile 
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Poster will feature updated results from Phase 2 portion of RINGSIDE, evaluating AL102 in desmoid tumors 
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring Committee
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
INVESTIGATION: Halper Sadeh LLP Investigates LONE, KIN, GRA, ADXS; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / July 22, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Lonestar Resources US Inc. (OTCQX:LONE)... 
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
News headline image
INVESTIGATION ALERT: Halper Sadeh LLP Investigates JAX, STMP, IKNX, ADXS; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / July 11, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: J. Alexander's Holdings, Inc. (NYSE:JAX)... 
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
News headline image
INVESTIGATION ALERT: Halper Sadeh LLP Investigates CORE, CAI, BOCH, ADXS; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / July 10, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Core-Mark Holding Company, Inc.... 
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
News headline image
ADVAXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Advaxis, Inc. - ADXS
From Kahn Swick & Foti, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.